15 recruiting. 15 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 15 | Recruiting 15 |
Follow Schizophrenia: new trials by email Literature Review of Schizophrenia trials Research Report on Schizophrenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effect of KarXT on Urological Safety Xanomeline/trospium chloride - Schizophrenia | Phase 4 | Recruiting | Bristol-Myers Squibb | 60 | 2026-01-20 | 2026-10-19 |
| A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Valbenazine - Schizophrenia, Schizoaffective Disorder | Phase 4 | Recruiting | Neurocrine Biosciences | 100 | 2025-08-29 | 2026-09-18 |
| Anticholinergic Deprescription in Schizophrenia Anticholinergic Deprescription, No Anticholinergic Deprescription - Schizophrenia, Schizoaffective Disorder | Phase 4 | Recruiting | Deepak K. Sarpal, M.D. | 105 | 2025-02-01 | 2026-07-10 |
| Biomarkers to Enhance Early Schizophrenia Treatment aripiprazole, risperidone, clozapine - Schizophenia Disorder | Phase 4 | Recruiting | Northwell Health | 180 | 2024-09-04 | 2026-07-31 |
| The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. Clozapine, Second-line Antipsychotics (treatment as usual) - Schizophrenia and Related Disorders, Early Treatment-Resistance | Phase 4 | Recruiting | Dr. Inge Winter | 418 | 2024-08-01 | 2025-09-26 |
| Anti-Inflammatory Challenge in Schizophrenia Infliximab, Placebo - Schizophrenia | Phase 4 | Recruiting | Emory University | 60 | 2024-04-18 | 2026-06-03 |
| Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia Lumateperone, Placebo - Schizophrenia, Schizo Affective Disorder | Phase 4 | Recruiting | University of Massachusetts, Worcester | 50 | 2024-04-02 | 2026-05-22 |
| Safety and Tolerability of Open-Labeled Iloperidone in Adolescents Iloperidone - Schizophrenia, Bipolar I Disorder | Phase 4 | Recruiting | Vanda Pharmaceuticals | 100 | 2023-05-24 | 2026-10-01 |
| "Extended" (Alternate Day) Antipsychotic Dosing Risperidone, Olanzapine, paliperidone - Schizophrenia and Related Disorders, Drug Administration Schedule | Phase 4 | Recruiting | Centre for Addiction and Mental Health | 120 | 2022-06-06 | 2026-04-13 |
| Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial Clozapine, treatment as usual - Schizophrenia, Schizoaffective Disorder | Phase 4 | Recruiting | New York State Psychiatric Institute | 280 | 2022-03-17 | 2026-05-04 |
| CLOZAPINE Response in Biotype-1 clozapine, risperidone - Schizophrenia, Schizoaffective Disorder | Phase 4 | Recruiting | University of Texas Southwestern Medical Center | 524 | 2022-03-01 | 2026-05-11 |
| Biomarkers in Clozapine-responding Schizophrenia Clozapine - Schizophrenia, Psychosis | Phase 4 | Recruiting | Jimmi Nielsen | 200 | 2021-02-28 | 2026-01-20 |
| Bazedoxifene -Treatment for Women With Schizophrenia Bazedoxifene Acetate, Placebo - Schizophrenia, Schizophreniform Disorders | Phase 4 | Recruiting | The Alfred | 160 | 2019-10-07 | 2026-06-03 |
| Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates Varenicline - Schizophrenia, Schizoaffective Disorder | Phase 4 | Recruiting | Corporal Michael J. Crescenz VA Medical Center | 10 | 2019-01-01 | 2019-03-22 |
| Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia Clozapine - Schizophrenia, Schizoaffective Disorder | Phase 4 | Recruiting | Centre for Addiction and Mental Health | 30 | 2016-10-15 | 2026-08-25 |
Psychotic Disorders (10) · Tardive Dyskinesia (2) · Bipolar Disorder (1) · Depressive Disorder, Major (1) · Inflammation (1) · Parkinsonian Disorders (1) · Tobacco Smoking (1)
Mental Disorders (15) · Schizophrenia Spectrum and Other Psychotic Disorders (15) · Pathological Conditions, Signs and Symptoms (3) · Central Nervous System Diseases (2) · Dyskinesia, Drug-Induced (2) · Dyskinesias (2) · Movement Disorders (2) · Nervous System Diseases (2) · Neurologic Manifestations (2) · Signs and Symptoms (2) · Basal Ganglia Diseases (1) · Behavior (1) · Bipolar and Related Disorders (1) · Brain Diseases (1) · Depressive Disorder (1)
Clozapine (6) · Risperidone (3) · Therapeutics (2) · Aripiprazole (1) · Infliximab (1) · Olanzapine (1) · Paliperidone Palmitate (1) · Varenicline (1) · bazedoxifene (1) · iloperidone (1) · lumateperone (1) · trospium chloride (1) · valbenazine (1) · xanomeline (1)
Centre for Addiction and Mental Health (2) · Bristol-Myers Squibb (1) · Corporal Michael J. Crescenz VA Medical Center (1) · Deepak K. Sarpal, M.D. (1) · Dr. Inge Winter (1) · Emory University (1) · Jimmi Nielsen (1) · Neurocrine Biosciences (1) · New York State Psychiatric Institute (1) · Northwell Health (1) · The Alfred (1) · University of Massachusetts, Worcester (1) · University of Texas Southwestern Medical Center (1) · Vanda Pharmaceuticals (1)
United States (10) · Canada (3) · Australia (1) · Austria (1) · Denmark (1) · Germany (1) · Italy (1) · Spain (1) · United Kingdom (1)
Carol Tamminga, M.D. (1) · David R Goldsmith, MD (1) · Deepak K Sarpal, M.D. (1) · Gary J Remington, MD, PhD (1) · Gary Remington, MD, PhD (1) · Jimmi Nielsen, PhD (1) · Ragy Girgis, MD (1) · Stanley N Caroff, MD (1) · Xiaoduo Fan, MD (1)
2023 (1), R01MH120317 (1), R01MH131910 (1), R01MH134883 (1), R01MH135096 (1)